Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer

Takayuki Iwamoto, Giampaolo Bianchini, Yuan Qi, Massimo Cristofanilli, Anthony Lucci, Wendy A. Woodward, James M. Reuben, Junji Matsuoka, Yun Gong, Savitri Krishnamurthy, Vicente Valero, Gabriel N. Hortobagyi, Fredika Robertson, W. Fraser Symmans, Lajos Pusztai, Naoto T. Ueno

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.

Original languageEnglish
Pages (from-to)785-795
Number of pages11
JournalBreast Cancer Research and Treatment
Volume125
Issue number3
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Inflammatory Breast Neoplasms
Breast Neoplasms
Gene Expression
Protein Biosynthesis
Lipid Metabolism
Genes

Keywords

  • cDNA microarray
  • Gene set analysis
  • Inflammatory breast cancer
  • Receptor subtypes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. / Iwamoto, Takayuki; Bianchini, Giampaolo; Qi, Yuan; Cristofanilli, Massimo; Lucci, Anthony; Woodward, Wendy A.; Reuben, James M.; Matsuoka, Junji; Gong, Yun; Krishnamurthy, Savitri; Valero, Vicente; Hortobagyi, Gabriel N.; Robertson, Fredika; Symmans, W. Fraser; Pusztai, Lajos; Ueno, Naoto T.

In: Breast Cancer Research and Treatment, Vol. 125, No. 3, 02.2011, p. 785-795.

Research output: Contribution to journalArticle

Iwamoto, T, Bianchini, G, Qi, Y, Cristofanilli, M, Lucci, A, Woodward, WA, Reuben, JM, Matsuoka, J, Gong, Y, Krishnamurthy, S, Valero, V, Hortobagyi, GN, Robertson, F, Symmans, WF, Pusztai, L & Ueno, NT 2011, 'Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer', Breast Cancer Research and Treatment, vol. 125, no. 3, pp. 785-795. https://doi.org/10.1007/s10549-010-1280-6
Iwamoto, Takayuki ; Bianchini, Giampaolo ; Qi, Yuan ; Cristofanilli, Massimo ; Lucci, Anthony ; Woodward, Wendy A. ; Reuben, James M. ; Matsuoka, Junji ; Gong, Yun ; Krishnamurthy, Savitri ; Valero, Vicente ; Hortobagyi, Gabriel N. ; Robertson, Fredika ; Symmans, W. Fraser ; Pusztai, Lajos ; Ueno, Naoto T. / Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. In: Breast Cancer Research and Treatment. 2011 ; Vol. 125, No. 3. pp. 785-795.
@article{5daf1beb1b314a25aaed5d2f5762542c,
title = "Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer",
abstract = "The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.",
keywords = "cDNA microarray, Gene set analysis, Inflammatory breast cancer, Receptor subtypes",
author = "Takayuki Iwamoto and Giampaolo Bianchini and Yuan Qi and Massimo Cristofanilli and Anthony Lucci and Woodward, {Wendy A.} and Reuben, {James M.} and Junji Matsuoka and Yun Gong and Savitri Krishnamurthy and Vicente Valero and Hortobagyi, {Gabriel N.} and Fredika Robertson and Symmans, {W. Fraser} and Lajos Pusztai and Ueno, {Naoto T.}",
year = "2011",
month = "2",
doi = "10.1007/s10549-010-1280-6",
language = "English",
volume = "125",
pages = "785--795",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer

AU - Iwamoto, Takayuki

AU - Bianchini, Giampaolo

AU - Qi, Yuan

AU - Cristofanilli, Massimo

AU - Lucci, Anthony

AU - Woodward, Wendy A.

AU - Reuben, James M.

AU - Matsuoka, Junji

AU - Gong, Yun

AU - Krishnamurthy, Savitri

AU - Valero, Vicente

AU - Hortobagyi, Gabriel N.

AU - Robertson, Fredika

AU - Symmans, W. Fraser

AU - Pusztai, Lajos

AU - Ueno, Naoto T.

PY - 2011/2

Y1 - 2011/2

N2 - The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.

AB - The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.

KW - cDNA microarray

KW - Gene set analysis

KW - Inflammatory breast cancer

KW - Receptor subtypes

UR - http://www.scopus.com/inward/record.url?scp=79151482682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151482682&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1280-6

DO - 10.1007/s10549-010-1280-6

M3 - Article

VL - 125

SP - 785

EP - 795

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -